Monday, October 12, 2015
ProtocolBuilder, a first-of-its-kind solution for writing clinical trial protocols, has received Gold Awards for “Best New Service Award or Application” and “Health Application” in the 2015 [app] design awards sponsored by design100. The awards celebrate creativity and innovation in design achievements by app creators and commissioners.
Arena Pharmaceuticals has announced that, at the request of the board of directors, company President and CEO Jack Lief has retired from the company, including the board. Dr. Harry Hixson, a director of Arena since 2004, has been appointed to serve as interim chief executive officer and interim principal financial officer. Arena will immediately initiate a search for a new chief executive.
The Nobel Assembly honored three scientists Monday for the drugs they have developed against tropical diseases, neglected and otherwise.
EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.
Exelixis has announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase III trial. William Berg, M.D., has joined the company as senior vice president of medical affairs, Jonathan Berndt as vice president of sales, and Gregg Bernier as vice president of marketing.